Iodide

Iodide

SCHEMBL1763607

CN=C(N)SC.I

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG

The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11624372 0.97
SCHEMBL13850734 0.97
SCHEMBL999515 0.97
Trifluoromethanesulfonic Acid SCHEMBL1001969 0.74 KDM4E (0.38)
Iodide SCHEMBL3998952 0.73
Iodide SCHEMBL5918335 0.73
SCHEMBL18157284 0.72 NOS1 (0.35)
SCHEMBL620843 0.69
SCHEMBL11946108 0.69
SCHEMBL1767791 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4041393-B1 NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES BAYER AG (DE) 2026-04-08 EP disclosed
CN-114867529-B Novel heteroaryl triazole compounds as pesticides 拜耳公司 2024-09-27 CN disclosed
CN-117567338-A Novel heteroaryl triazole compounds as pesticides 拜耳公司 2024-02-20 CN disclosed
US-20230028441-A1 NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES ELANCO ANIMAL HEALTH GMBH (DE) 2023-01-26 US disclosed
EP-4041393-A1 NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES Bayer Aktiengesellschaft (DE) 2022-08-17 EP disclosed
WO-2021069567-A1 NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES BAYER AKTIENGESELLSCHAFT (DE) 2021-04-15 WO disclosed
US-10913769-B2 Synthetic peptide amides and dimers thereof CARA THERAPEUTICS, INC. (US) 2021-02-09 US disclosed
US-20190177365-A1 SYNTHETIC PEPTIDE AMIDES AND DIMERS THEREOF CARA THERAPEUTICS, INC. (US) 2019-06-13 US disclosed
US-10017536-B2 Synthetic peptide amides and dimers thereof CARA THERAPEUTICS, INC. (US) 2018-07-10 US disclosed
US-20160376308-A1 SYNTHETIC PEPTIDE AMIDES AND DIMERS THEREOF CARA THERAPEUTICS, INC. (US) 2016-12-29 US disclosed
US-20090264373-A1 of kappa opioid receptor and agonists thereof, exhibit low P450 CYP inhibition and low penetration into the brain; visceral pain, neuropathic pain, hyperalgesia, irritabile bowel syndrome, ocular and otic inflammation, pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma CARA THERAPEUTICS, INC. (US) 2009-10-22 US disclosed
EP-2079756-A2 SYNTHETIC PEPTIDE AMIDES AND DIMERS THEREOF Cara Therapeutics, Inc. (US) 2009-07-22 EP disclosed
US-20090156508-A1 SYNTHETIC PEPTIDE AMIDES AND DIMERIC FORMS THEREOF CARA THERAPEUTICS, INC. (US) 2009-06-18 US disclosed
WO-2008060552-A2 SYNTHETIC PEPTIDE AMIDES AND DIMERS THEREOF CARA THERAPEUTICS, INC. (US) 2008-05-22 WO disclosed
US-5883130-A Ng-monomethyl-l-arginine hydrochloride derivatives and their use in the treatment of septic shock GLAXO WELLCOME INC. (US) 1999-03-16 US disclosed
US-5856565-A Ng-monomethyl-l-argine hydrochloride derivatives and their use in the treatment of septic shock GLAXO WELLCOME, INC. (US) 1999-01-05 US disclosed
US-5767312-A NG -monomethyl-L-arginine hydrochloride derivatives and their use in the treatment of septic shock GLAXO WELLCOME, INC. (US) 1998-06-16 US disclosed
EP-0651741-B1 NG-MONOMETHYL-L-ARGININE HYDROCHLORIDE DERIVATIVES AND PROCESS FOR THEIR PREPARATION WELLCOME FOUND (GB) 1997-01-29 EP disclosed
EP-0651741-A1 N?G -MONOMETHYL-L-ARGININE HYDROCHLORIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF SEPTIC SHOCK. WELLCOME FOUND (GB) 1995-05-10 EP disclosed
WO-1994002453-A1 NG-MONOMETHYL-L-ARGININE HYDROCHLORIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF SEPTIC SHOCK THE WELLCOME FOUNDATION LIMITED (GB) 1994-02-03 WO disclosed